ANCA-Associated Vasculitis: An Update

被引:93
|
作者
Almaani, Salem [1 ]
Fussner, Lynn A. [2 ]
Brodsky, Sergey [3 ]
Meara, Alexa S. [4 ]
Jayne, David [5 ]
机构
[1] Ohio State Univ, Div Nephrol, Wexner Med Ctr, Columbus, OH 43201 USA
[2] Ohio State Univ, Div Pulm & Crit Care Med, Wexner Med Ctr, Columbus, OH 43201 USA
[3] Ohio State Univ, Dept Pathol, Wexner Med Ctr, Columbus, OH 43201 USA
[4] Ohio State Univ, Div Rheumatol, Wexner Med Ctr, Columbus, OH 43201 USA
[5] Univ Cambridge, Dept Med, Cambridge CB2 0QQ, England
关键词
ANCA vasculitis; review; vasculitis; crescentic glomerulonephritis; ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; DAILY ORAL CYCLOPHOSPHAMIDE; CHURG-STRAUSS-SYNDROME; WEGENERS-GRANULOMATOSIS; MICROSCOPIC POLYANGIITIS; PLASMA-EXCHANGE; MAINTENANCE THERAPY; RANDOMIZED-TRIAL; RISK-FACTORS; REMISSION-MAINTENANCE;
D O I
10.3390/jcm10071446
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a group of small vessel vasculitides characterized by granulomatous and neutrophilic tissue inflammation, often associated with the production of antibodies that target neutrophil antigens. The two major antigens targeted by ANCAs are leukocyte proteinase 3 (PR3) and myeloperoxidase (MPO). AAV can be classified into 3 categories based on patterns of clinical involvement: namely, granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic GPA (EGPA). Clinically, AAV involves many organ systems including the lungs, kidneys, skin, and nervous system. The prognosis of AAV has improved dramatically due to advances in the understanding of its pathogenesis and treatment modalities. This review will highlight some of the recent updates in our understanding of the pathogenesis, clinical manifestations, and treatment options in patients with AAV focusing on kidney involvement.
引用
收藏
页数:22
相关论文
共 50 条
  • [21] Update on the Treatment of ANCA-associated Vasculitis
    Holle, Julia U.
    Moosig, Frank
    AKTUELLE RHEUMATOLOGIE, 2019, 44 (04) : 276 - 283
  • [22] Pathogenesis of ANCA-Associated Vasculitis, an Update
    Kallenberg, Cees G. M.
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2011, 41 (02) : 224 - 231
  • [23] ANCA-associated renal vasculitis
    Savage, COS
    Harrington, JT
    Saville, J
    Rees, A
    Duffield, J
    Dillon, M
    Watson, A
    Powis, S
    Pusey, C
    Davison, A
    Iggo, N
    Reaich, D
    Roberts, I
    Mathieson, P
    Bone, J
    Stuart, L
    Gaskin, G
    Whitworth, C
    Ritz, E
    KIDNEY INTERNATIONAL, 2001, 60 (04) : 1614 - 1627
  • [24] Epidemiology of ANCA-associated Vasculitis
    Ntatsaki, Eleana
    Watts, Richard A.
    Scott, David G. I.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2010, 36 (03) : 447 - +
  • [25] The immunopathology of ANCA-associated vasculitis
    McKinney, Eoin F.
    Willcocks, Lisa C.
    Broecker, Verena
    Smith, Kenneth G. C.
    SEMINARS IN IMMUNOPATHOLOGY, 2014, 36 (04) : 461 - 478
  • [26] Rituximab in ANCA-Associated Vasculitis
    Hassan, Romina I.
    Gaffo, Angelo L.
    CURRENT RHEUMATOLOGY REPORTS, 2017, 19 (02)
  • [27] Pathogenesis of ANCA-associated Vasculitis
    Flint, Julia
    Morgan, Matthew D.
    Savage, Caroline O. S.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2010, 36 (03) : 463 - +
  • [28] Treatment of Severe and/or Refractory ANCA-Associated Vasculitis
    Guillevin, Loic
    CURRENT RHEUMATOLOGY REPORTS, 2014, 16 (08)
  • [29] Diagnosis and management of ANCA-associated vasculitis
    Kronbichler, Andreas
    Bajema, Ingeborg M.
    Bruchfeld, Annette
    Kirsztajn, Gianna Mastroianni
    Stone, John H.
    LANCET, 2024, 403 (10427) : 683 - 698
  • [30] Renal Involvement in ANCA-associated vasculitis
    Kronbichler, Andreas
    Windpessl, Martin
    AKTUELLE RHEUMATOLOGIE, 2020, 45 (02) : 141 - 149